Ponazuril
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione | |
| Clinical data | |
| Trade names | Marquis |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 69004-04-2 |
| ATCvet code | QP51AJ04 |
| PubChem | CID 3050408 |
| ChemSpider | 2312474 |
| UNII |
JPW84AS66U  |
| Chemical data | |
| Formula | C18H14F3N3O6S |
| Molar mass | 457.380 g/mol |
| |
| |
| (verify) | |
Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.[1][2] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
See also
References
- ↑ Marquis FDA Professional Drug Information
- ↑ MacKay, R. J.; Tanhauser, S. T.; Gillis, K. D.; Mayhew, I. G.; Kennedy, T. J. (2008). "Effect of intermittent oral administration of ponazuril on experimentalSarcocystis neuronainfection of horses". American Journal of Veterinary Research 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.
This article is issued from Wikipedia - version of the Friday, August 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.